



Optical Coherence Tomography as a Novel Diagnostic Tool for Distal Type Chronic Thromboembolic Pulmonary Hypertension

Shunsuke Tatebe, MD; Yoshihiro Fukumoto, MD, PhD; Koichiro Sugimura, MD, PhD;
 Makoto Nakano, MD, PhD; Saori Miyamichi, MD; Kimio Satoh, MD, PhD;
 Minako Oikawa, MD, PhD; Hiroaki Shimokawa, MD, PhD

The new classification of pulmonary hypertension (PH) has been recently updated,¹ in which 5 major categories of the disorder have been classified. Among them, pulmonary arterial hypertension (PAH, class 1) and chronic thromboembolic PH (CTEPH, class 4) are characterized as having similar hemodynamic pulmonary circulation despite their different pathological vascular structures.

Optical coherence tomography (OCT) is an interferometer-based optical imaging modality that produces a 2-dimensional image of optical scattering from internal tissue micro-

structures with a high resolution of approximately 10–20 μm, 10-fold higher than that of intravascular ultrasound.^{2–4} Here, we report the potential usefulness of OCT as a novel diagnostic tool for the differential diagnosis of distal type CTEPH from PAH.

The Ethics Committees of Tohoku University Hospital approved the study protocol and all patients provided written informed consent. We prospectively enrolled 31 consecutive patients with PH, including PAH (n=17), CTEPH (n=9), and normal hemodynamic subjects (control, n=5), who were

Table. Subject Characteristics				
	Control	PAH	CTEPH	P value
n	6	18	9	
Age (years)	64.2±4.7	45.6±3.7	60.2±4.4	<0.05
Gender, n (%)				
Male	1 (17)	6 (33)	0 (0)	NS
Female	5 (83)	12 (67)	9 (100)	NS
Type of PH, n (%)				
IPAH	–	6 (33)	–	
CTD-PAH	–	9 (50)	–	
CHD-PAH	–	2 (11)	–	
Portal hypertension-PAH	–	1 (6)	–	
Hemodynamic variables				
PCWP (mmHg)	9±1	8±1	9±1	NS
Mean PAP (mmHg)	15±1	42±4	42±4	NS
CI (L · ml ⁻¹ · m ⁻²)	2.8±0.3	2.9±0.2	3.0±0.2	NS
Mean PVR (dyne · s ⁻¹ · cm ⁻⁵)	130±28	718±149	585±80	NS
OCT findings, n (%)				
Thrombus formation	0 (0)	0 (0)	4 (44)	<0.05
Luminal flaps	0 (0)	0 (0)	6 (67)	<0.01

Data are expressed as mean ± SEM. Statistical analysis was performed between PAH and CTEPH, using unpaired t-test for continuous variables and chi-square test for categorical variables, using Stat View (SAS Institute, Cary, NC, USA).

PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; PH, pulmonary hypertension; IPAH, idiopathic PAH; CTD, connective tissue disease; CHD, congenital heart disease; PCWP, pulmonary capillary wedge pressure; PAP, pulmonary arterial pressure; CI, cardiac index; PVR, pulmonary vascular resistance; OCT, optical coherence tomography.

Received February 22, 2010; revised manuscript received April 8, 2010; accepted April 29, 2010; released online May 22, 2010 Time for primary review: 42 days


Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

The Guest Editor for this article was Masaaki Ito, MD.

Mailing address: Yoshihiro Fukumoto, MD, PhD, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. E-mail: fukumoto@cardio.med.tohoku.ac.jp

ISSN-1346-9843 doi:10.1253/circj.CJ-10-0160

All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: cj@j-circ.or.jp



admitted to Tohoku University Hospital from February 2009 to December 2009 and underwent right heart catheterization including OCT (Table). Pulmonary arteries >1 mm in diameter had no obstruction in the control or PAH subjects, although the media of the arteries appeared to be thickened in PAH subjects compared with controls (Figures A,B). In contrast, in all cases of CTEPH, we obtained completely different findings as compared with the control or PAH subjects; half of the CTEPH patients had occlusion of the pulmonary arteries, probably by thrombus (Figure C), and more than half of them had flaps in the lumen of the pulmonary arteries (Figure D; Table).

Pathohistological studies have demonstrated that idiopathic PAH is associated with abnormal vascular structures, including medial and/or intimal hypertrophy, concentric and/or eccentric intimal fibrosis, obstruction in the arterial lumen, and aneurysmal dilatation in vessels <300 μm in diameter.⁵⁻⁷ In contrast, CTEPH is caused by the obstruction of pulmonary arteries by thrombus and is mainly observed in large vessels.^{8,9} The present results indicate that OCT is a potentially useful tool for the differential diagnosis of distal type CTEPH from PAH.

Acknowledgment

The present work was supported in part by grants-in-aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.

References

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2009; **54**: S43–S54.
2. Tanimoto T, Imanishi T, Tanaka A, Yamano T, Kitabata H, Takarada S, et al. Various types of plaque disruption in culprit coronary artery visualized by optical coherence tomography in a patient with unstable angina. *Circ J* 2009; **73**: 187–189.
3. Sawada T, Shite J, Negi N, Shinke T, Tanino Y, Ogasawara D, et al. Factors that influence measurements and accurate evaluation of stent apposition by optical coherence tomography: Assessment using a phantom model. *Circ J* 2009; **73**: 1841–1847.
4. Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, et al. Long-term follow-up of neointimal coverage of sirolimus-eluting stents: Evaluation with optical coherence tomography. *Circ J* 2009; **73**: 2300–2307.
5. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, et al. Primary pulmonary hypertension: Vascular structure, morphometry, and responsiveness to vasodilator agents. *Circulation* 1989; **80**: 1207–1221.
6. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: Expectation for Rho-kinase inhibitors. *Tohoku J Exp Med* 2007; **211**: 309–320.
7. Doe Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. *Circ J* 2009; **73**: 1731–1739.
8. Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: An updated review. *Curr Opin Cardiol* 2008; **23**: 555–559.
9. Yoshimi S, Tanabe N, Masuda M, Sakao S, Uruma T, Shimizu H, et al. Survival and quality of life for patients with peripheral type chronic thromboembolic pulmonary hypertension. *Circ J* 2008; **72**: 958–965.